RemdesivirThird Party Manufacturing in India

Remdesivir works as a broad-spectrum antiviral prodrug that interferes with viral RNA replication. Once administered intravenously, it is taken up by host cells and metabolized through a series of phosphorylation steps into its pharmacologically active form, remdesivir triphosphate, which closely resembles the natural nucleotide adenosine triphosphate (ATP).

This active metabolite acts as a competitive inhibitor of the viral RNA-dependent RNA polymerase (RdRp), the enzyme responsible for copying the viral genetic material. When the viral polymerase attempts to incorporate remdesivir triphosphate into the growing RNA chain instead of ATP, the modified nucleotide is successfully integrated. However, after three to five additional nucleotides are added, the incorporation of remdesivir causes delayed chain termination, effectively halting further elongation of the viral RNA strand. This prevents the virus from completing genome replication and producing new infectious particles.

Remdesivir has demonstrated antiviral activity against multiple families of RNA viruses including coronaviruses, filoviruses, and paramyxoviruses. Its prodrug design enhances intracellular delivery and activation of the active nucleotide, achieving significantly higher intracellular concentrations than the parent nucleoside alone. The drug is primarily metabolized in the liver and excreted via the kidneys.

Therapeutic Uses

Remdesivir is indicated for the treatment of:

• COVID-19 in Hospitalized Patients: Reduces recovery time and prevents disease progression in adults and pediatric patients with SARS-CoV-2 infection who require supplemental oxygen or are at high risk of progressing to severe disease.
• COVID-19 in Non-Hospitalized High-Risk Patients: Prevents hospitalization and death in patients with mild to moderate COVID-19 who are at high risk of progression, including those with advanced age, obesity, diabetes, or immunosuppression.
• Coronavirus Infections Beyond SARS-CoV-2: In vitro activity has been demonstrated against SARS-CoV, MERS-CoV, and other coronaviruses, though clinical use remains primarily for COVID-19.

Why Manufacturers Choose Remdesivir

Remdesivir was the first antiviral drug approved by the FDA for COVID-19 and remains a cornerstone therapy for hospitalized patients. Its widespread use during the pandemic established a massive global demand infrastructure that continues to drive procurement by government stockpiles and hospital formularies. The lyophilized powder for injection requires specific aseptic manufacturing capabilities, positioning contract manufacturers with sterile injectable facilities at a premium in the pharmaceutical outsourcing market.

This makes Remdesivir one of the most sought-after molecules for third party manufacturing in India, with consistent demand from export-oriented companies supplying regulated markets.